Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Genetic Aberration Paves the Way for New Treatment of Cancer Disease

Published: Friday, November 08, 2013
Last Updated: Friday, November 08, 2013
Bookmark and Share
Research was recently published in Scandinavian Journal of Gastroenterology.

Researchers from Faculty of Health and Medical Sciences, University of Copenhagen, have characterized a genetic aberration on a group of colorectal cancer patients.

The discovery gives hope for a new and efficient treatment of colorectal cancer, which is a frequent and often fatal disease.

12-15 years of development and millions of dollars are typically the costs, when companies develop a new anti-cancer drug.

Therefore all short cuts to a treatment are welcome. Researchers at Department of Veterinary Disease Biology, University of Copenhagen, recently discovered such a potential short cut.

“Our new research shows, that we might be able to introduce a treatment faster and cheaper than usual in the development of cancer treatment, and we estimate that it will be efficient in around 10 per cent of patients with colorectal cancer," says MD and PhD student Sune Nygård, Department of Veterinary Disease Biology, University of Copenhagen.

Re-use of existing breast cancer treatment
In the new study the researchers have shown that around 10 per cent of colorectal cancer patients harbor an aberration in the gene called TOP2A in their cancer cells. These tumors could potentially benefit from treatment with a specific chemotherapeutic drug - a so-called “anti-TOP2A treatment”, which is already used in breast cancer patients with this gene aberration.

Clinical study begins
Approximately 600,000 patients die of colorectal cancer each year worldwide.

“If the first treatment doesn’t cure a patient with colorectal cancer, the possibilities of additional treatment are limited,” says Nils Brünner, MD, professor at University of Copenhagen. “Therefore it is very important to find a new, efficient treatment,” he adds.

The research group from the Department of Veterinary Disease Biology and professor Per Pfeiffer at Odense University Hospital have received funds from The Danish Cancer Society to initiate a clinical trial.

Here it will be tested, if patients with the TOP2A gene defect could benefit from the targeted anti-TOP2A treatment.

“It is unique to go from a discovery in the laboratory towards a treatment for cancer patients at this pace. This is only possible when researchers and doctors work closely together,” says Nils Brünner, University of Copenhagen.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

EU Funding for Clinical Trials of a Placental Malaria Vaccine
PlacMalVac project has received an FP7 EU grant.
Tuesday, March 05, 2013
Scientific News
Liquid Biopsies: Utilization of Circulating Biomarkers for Minimally Invasive Diagnostics Development
Market Trends in Biofluid-based Liquid Biopsies: Deploying Circulating Biomarkers in the Clinic. Enal Razvi, Ph.D., Managing Director, Select Biosciences, Inc.
Study Questions Presence in Blood of Heart-Healthy Molecules from Fish Oil Supplements
A new study from the Perelman School of Medicine at the University of Pennsylvania questions the relevance of fish oil-derived SPMs and their purported anti-inflammatory effects in humans.
Experimental MERS Vaccine Shows Promise in Animal Studies
A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines.
Young South African Women can Adhere to Daily PrEP Regimen as HIV Prevention
NIH-funded study finds men in Bangkok, Harlem also successful in taking daily dose.
Key Player in Diabetic Kidney Disease Revealed
Discovery could lead to new and better diagnostic marker for chronic kidney disease.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Santhera Announces First Patient Dosing with Omigapil in CMD
Company announces full patient recruitment of CALLISTO study.
Study Shows Promise of Precision Medicine for Most Common Type of Lymphoma
The study appeared online July 20, 2015, in Nature Medicine.
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!